Thermo Fisher Scientific Dinutuximab Chimeric Recombinant Human Monoclonal Antibody

Applications

• ELISA (Assay-dependent)

Product Specifications

Product Specific Information

• Endotoxin level < 0.01 EU/µg (LAL method)
• Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
• Store at 2–8°C for one week or at -20 to -80°C for up to twelve months from the date of receipt.

Target Information

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues.
It consists of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain.
By binding to GD2, dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of tumor cells, leading to apoptosis and inhibition of proliferation.
It is indicated, in combination with GM-CSF, IL-2, and 13-cis-retinoic acid, for the treatment of pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior multimodal therapy.
Despite high clinical response rates, complete eradication of neuroblastoma is rare, and relapse is common. Immunotherapy with dinutuximab targets residual neuroblastoma cells to prevent recurrence.

For Research Use Only.
Not for use in diagnostic procedures. Not for resale without express authorization.